Background

For patients with End-Stage Renal Disease (ESRD) awaiting organ transplantation, the harshest barrier is the antibody defense wall built by the body's immune system. Highly sensitized patients, who have formed anti-Human Leukocyte Antigen (HLA) antibodies due to past pregnancy, blood transfusions, or previous organ transplants, are immediately disqualified during crossmatch tests even when a donor organ is allocated. This is the reality for patients with a calculated Panel Reactive Antibody (cPRA) exceeding 99.9%, where the probability of finding a compatible organ among tens of thousands of donors is less than 0.005%, leaving them with no choice but lifelong hemodialysis.

In existing clinical practice, attempts were made to lower antibody concentrations using plasmapheresis to physically filter antibodies from the blood, intravenous immunoglobulin (IVIG) administration, and combination therapy with Rituximab to suppress B cells. These desensitization therapies merely diluted antibodies in the circulating blood temporarily and did not provide a long-term solution. This was because they failed to completely eradicate long-lived plasma cells and memory B cells residing deep within the bone marrow and lymphatic tissues. Upon cessation of treatment, a rebound phenomenon followed, characterized by plasma cells secreting donor-specific antibodies and causing antibody levels to surge back to baseline. This confirmed that transplant success in highly sensitized patients is unlikely unless the 'cell factories' themselves, which continuously produce antibodies, are blocked at their source. This is why there was an urgent need for a next-generation immunotherapy strategy to directly target the roots of humoral immune memory.

Key Findings

A research team at the University of Pennsylvania Perelman School of Medicine introduced Chimeric Antigen Receptor T-cell (CAR-T) technology, which has proven successful in oncology, into organ transplant desensitization. They developed an autologous dual CAR-T cell therapy strategy that targets both CD19 on the surface of memory B cells and B-cell Maturation Antigen (BCMA) on the surface of antibody-secreting plasma cells. The concept was to completely break the antibody production chain by attacking both the upstream and downstream cells responsible for antibody production.

Two highly sensitized ESRD patients, whose cPRA levels reached 99.995% and 99.998%, leading to their long-term exclusion from the transplant waiting list, were enrolled in the clinical trial. Both patients underwent lymphodepleting preconditioning chemotherapy and received intravenous administration of CD19-targeted CAR-T and BCMA-targeted CAR-T cells. As a result of the cell therapy administered to the patient proliferating explosively and precisely targeting cells in the bone marrow and blood, the level of anti-HLA antibodies in the patient's blood showed a sharp downward curve several weeks after administration.

In vivo clearance patterns of low-titer and moderate-titer antibodies with a Mean Fluorescence Intensity (MFI) below 6000. As the antibody barrier was sufficiently lowered, the two patients were finally allocated kidneys from brain-dead donors and successfully underwent transplant surgery. No hyperacute rejection, a common concern immediately after surgery, was observed. During the subsequent follow-up period after transplantation, stable maintenance of graft kidney function was confirmed without evidence of acute Antibody-Mediated Rejection (AMR) upon biopsy.

Significance and Outlook

This clinical result is considered the first proof-of-concept case expanding CAR-T cells, previously regarded as treatments for oncologic hematology, into the field of solid organ transplantation. It is evaluated as opening a new therapeutic pathway for ultra-sensitized patients who have long been denied transplant opportunities. It demonstrates the potential for application not only to kidney transplantation but also to heart or lung transplant candidates, whose access to donor organs was previously limited by the risk of immune rejection. It holds potential as a universal platform for suppressing autoantibody production across the spectrum of humoral immune diseases.

Voices in the academic community also point out the boundaries of therapeutic efficacy and realistic limitations. It has been noted that for ultra-high-affinity antibodies with an MFI exceeding 6000, this dual-targeting therapy alone was insufficient to achieve complete eradication. The time and cost required for patient-specific autologous cell manufacturing, as well as the risk of infection due to pre-treatment and side effects such as cytokine release syndrome (CRS), remain challenges to be addressed. In the future, the discovery of combination drugs to control high-titer antibodies and the development of gene-editing-based allogeneic off-the-shelf cell therapies will be key to clinical mass adoption. It is a critical time for designing large-scale multicenter clinical trials to further verify immunological safety.